10-K: Skinvisible Inc. Reports Full Year 2023 Results, Cites Progress in Clinical Trials

Skinvisible, Inc. reports a net loss of $2.38 million for 2023, while highlighting advancements in clinical trials by its licensee, Quoin Pharmaceuticals.

Summary

• Skinvisible, Inc., a pharmaceutical research and development company, reported a net loss of $2.38 million for the year ended December 31, 2023, compared to a net loss of $1.22 million in 2022.
• The company's revenue decreased to $20,000 in 2023 from $279,296 in 2022, primarily due to a reduction in licensing fees.
• Operating expenses decreased slightly to $510,375 in 2023 from $512,919 in 2022, with the majority of expenses related to salaries and wages and audit and accounting fees.
• Other expenses increased significantly to $1.89 million in 2023 from $986,455 in 2022, mainly due to interest expenses.
• The company's accumulated deficit as of December 31, 2023, was $39.38 million.
• Skinvisible is dependent on licensing its patented Invisicare technology and is exploring opportunities in large medical markets outside of dermatology.
• The company's licensee, Quoin Pharmaceuticals, has made significant progress in clinical trials for a product using Invisicare technology targeting Netherton Syndrome, including positive initial data and FDA clearance to recruit teen subjects.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, declining revenue, and a going concern warning. While there is positive news regarding clinical trial progress, the overall sentiment is negative due to the company's financial instability.

Positives

• Quoin Pharmaceuticals has achieved positive initial data and a clean safety profile in clinical trials for a product using Skinvisible's Invisicare technology.
• Quoin has received FDA clearance to recruit teen subjects into its Netherton Syndrome clinical studies, potentially expediting recruitment and leading to a more robust data set.
• The company's gross profit margin was 100% in 2023 due to licensing revenue.
• Skinvisible has completed research and development on forty products and has numerous patents issued.

Negatives

• Skinvisible experienced a significant decrease in revenue, from $279,296 in 2022 to $20,000 in 2023.
• The company's net loss increased to $2.38 million in 2023 from $1.22 million in 2022.
• The company has a working capital deficit of $3,476,947 as of December 31, 2023.
• Skinvisible has outstanding secured notes payable of $433,600 that are past due and in default.
• The company has a history of losses and an accumulated deficit of $39,380,488 as of December 31, 2023.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company has outstanding secured and unsecured debt that has matured and has not been paid off, which could negatively affect its ability to continue as a going concern.
• Skinvisible needs to raise additional funds to achieve its future strategic objectives, and there is no guarantee that it will be able to obtain additional debt or equity financing on favorable terms.
• The company has a history of losses and may not be able to generate sufficient revenues to cover its expenses.
• The company relies on third parties to manufacture its products, which exposes it to factors outside of its control.
• The company is subject to product liability claims and may be exposed to claims relating to product advertising or product quality.
• The company's business may be adversely affected by unfavorable publicity within the skin care markets.
• The company is exposed to local business risks in different countries as it conducts international business transactions.
• The company's commercial success depends on its ability to develop and commercialize its potential products without infringing the intellectual property rights of third parties.
• The company's success depends on continuing to hire and retain qualified personnel.
• The company's stock is thinly traded and may be difficult to sell without significantly depressing the value of the stock.

Future Outlook

The company intends to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. They plan to seek additional financing in a private equity offering to secure funding for operations.

Management Comments

• Management believes that the skin care market and personal care markets are significantly affected by national media attention.
• Management believes that the company's products have clear scientific advantages and marketing messages which resonate with physicians and consumers.
• Management plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding.

Industry Context

The document highlights the competitive nature of the skincare and pharmaceutical industries, noting that many companies are seeking unique delivery systems and that Skinvisible's competitors may have greater resources. The company's business model of out-licensing its technology is a response to the trend of pharmaceutical companies downsizing their internal R&D departments.

Comparison to Industry Standards

• The document does not provide specific financial benchmarks for comparison to industry standards.
• However, the company's reliance on licensing revenue is a common model for early-stage biotech and pharmaceutical companies.
• The company's focus on a patented delivery system is similar to other companies in the pharmaceutical and skincare industries that seek to differentiate their products through innovative technology.
• The company's partnership with Quoin Pharmaceuticals is similar to other collaborations between smaller biotech companies and larger pharmaceutical firms.
• The document does not provide specific details on the performance of comparable companies or projects, making a direct comparison difficult.

Related Party Transactions

• The company has convertible notes payable to related parties, including its officers.
• The company has loans from related parties.
• The company has transactions with Ovation Science Inc., a related party, including a license agreement and sales of polymer products.

Stakeholder Impact

• Shareholders face the risk of losing their entire investment due to the company's financial instability and going concern issues.
• Employees may be impacted by the company's financial difficulties and potential need for cost-cutting measures.
• Customers and licensees may be affected by the company's ability to continue operations and deliver products.
• Creditors face the risk of not being repaid due to the company's outstanding debt and financial challenges.

Next Steps

• The company plans to seek additional financing through a private equity offering.
• The company will continue to focus on licensing its core products.
• The company will continue to monitor the progress of Quoin's clinical trials.
• The company will work to address the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

Invisicare, licensing, pharmaceutical, dermatology, clinical trials, Netherton Syndrome, topical, polymer delivery system, FDA, skincare